Navigation Links
Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments

Individuals with moderate to severe chest pains (angina) who have not found relief from medication may benefit from a new gene therapy approach being used by cardiologists at Rush University Medical Center to grow new blood vessels in the heart.

The phase II clinical research study uses vascular endothelial growth factor-2 (VEGF-2) in the form of a solution containing a DNA plasmid that is delivered using catheterization to heart tissue that has been damaged from insufficient blood flow.

Once the catheter reaches the targeted site inside of the heart, the VEGF-2 is injected into the heart muscle region with inadequate blood supply. The DNA plasmid is then taken up by the middle muscular layer of the heart wall near the injection site. Inside the cell, the DNA encoded VEGF-2 expresses itself which in turn stimulates the growth of new blood vessels by promoting the proliferation of endothelial cells in the heart.

New blood vessels are required to provide oxygen-carrying blood to heart muscles to compensate for the blocked heart arteries. The subsequent, improved blood flow relieves the painful symptoms of angina.

"The process of growing new blood vessels, or angiogenesis, should occur over the course of four to eight weeks following the procedure which is done in the cardiac catheterization lab at Rush," said Dr. Gary L. Schaer, the principal investigator of the trial at Rush and director of the Rush Cardiac Catheterization Labs. "The patient goes home the next day." Several patients have received the gene therapy and all are doing well.

Individuals who may be candidates for this gene therapy study trial must have moderate to severe angina, but cannot also be candidates for treatment using angioplasty or bypass surgery. Angioplasty involves a catheterization with a balloon-like device that opens blocked arteries, while bypass surgery requires open-heart surgery to place veins removed from the patient's leg or arteries taken from the patient's chest wall or arm to "bypass" the blocked blood vessels.

While both of these treatments have been shown to be successful in relieving severe chest pains resulting from blocked arteries, a significant percentage of patients eventually do not respond well to either treatment, often requiring another angioplasty or bypass operation, noted Schaer. "If gene therapy proves to be safe and effective, it will represent an important new approach to improve the quality of life in these seriously ill patients with refractory chest pain," said Dr. R. Jeffrey Snell, study co-investigator and Schaer's colleague at Rush.

In the new study, patients will be randomly assigned to receive the gene administered through a cardiac catheter threaded into the heart from a leg artery or a placebo delivered using the same method. As required by the U.S. Food and Drug Administration, the study is "double blinded," which means that neither the doctor nor the patient will know whether he or she is receiving the gene therapy or a placebo. For every three patients that receive the active gene, one will receive a placebo. Following treatment, patients enrolled in the study will be examined for chest pain at one month, three months and six months. A total of 404 patients will be enrolled in the study at the 20 study sites across the country.

The Genetic Angiogenic Stimulation Investigational Study (GENASIS) is funded by Corautus Genetics.

More than 11 million people in the United States suffer from coronary artery disease. Many patients receive medications to increase blood flow but nearly 500,000 angioplasties and coronary bypass procedures are performed each year in those patients who do not benefit from medication.


'"/>

Source:Rush University Medical Center


Related biology news :

1. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
2. Researchers Closer To Helping Hearing-Impaired Using Stem Cells
3. Using nanoparticles, in vivo gene therapy activates brain stem cells
4. Using computers and DNA to count bacteria
5. Using the genomic shortcut to predict bacterial behavior
6. Using natures most primitive anti-viral defense system to find new approaches to cancer research
7. Using dental X-rays to detect osteoporosis
8. Using brain scans, researchers find evidence for a two-stage model of human perceptual learning
9. Using nanomagnets to enhance medical imaging
10. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
11. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/8/2016)... Kingdom , Jan. 8, 2016   Bruin Biometrics, ... today announced the closing of a $9 million financing. The ... the financing will be used to accelerate the commercialization of ... early-stage pressure ulcers. United Kingdom ... Mark approval. The device,s introduction has been met with enthusiasm ...
(Date:1/7/2016)... , Jan. 7, 2016 Various factors ... biopharmaceutical products such as biologics and biosimilars. Some ... reduce healthcare expenditure, growing demand for cost-effective alternatives, ... population. Biosimilars are similar versions of their corresponding ... to their quality, safety, and efficacy. The global ...
(Date:1/6/2016)... , Jan. 6, 2016 Based ... market, Frost & Sullivan recognizes MorphoTrak, LLC, a ... North American Frost & Sullivan Company of the ... fingerprint scanning technology, Morpho Wave™ , has consolidated ... the fingerprint biometrics market. Morpho Wave is ...
Breaking Biology News(10 mins):
(Date:2/3/2016)... ... February 03, 2016 , ... ... and Unix visualization solutions today announced the addition of a powerful “Session Preview” ... to see the current state of the remote Linux desktop or other applications ...
(Date:2/3/2016)... , Feb. 3, 2016  Silk Therapeutics, Inc., today announced ... Silk Therapeutics has now raised a total of $10.25 million ... the company. The Series A2 round was led by existing ... , with participation from new investors Lear Corporation and Highland ... Roy P. Disney ; Richard Sackler , MD, with ...
(Date:2/3/2016)... NY (PRWEB) , ... February 03, 2016 , ... ... new products to aid in the rapid development and ongoing quality control of ... Zika Virus outbreak is extremely high,” Dr. Gregory R. Chiklis, President and CEO ...
(Date:2/3/2016)... (PRWEB) , ... February 03, 2016 , ... ... silicon (Si) and InGaAs chips and wafers, and InP epi wafers based in ... from silicon detectors–including photodiodes, photo transistors, and Avalanche photodiodes–to Si and InGaAs PIN ...
Breaking Biology Technology: